Trial · NCT01982695
Cardiomyopathy in DMD: Lisinopril vs. Losartan
NCT01982695, Not applicable, Completed, Nationwide Children's Hospital; results first posted 2017-03-21
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Cardiomyopathy in DMD: Lisinopril vs. Losartan. Trials, record NCT01982695. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01982695
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Cardiomyopathy in DMD: Lisinopril vs. Losartan
- NCT number
- NCT01982695
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 23 participants, actual
- Lead sponsor
- Nationwide Children's Hospital
- Conditions
- Duchenne Muscular Dystrophy (DMD), Cardiomyopathy
- Interventions
- Losartan, Lisinopril
- First posted
- 2013-11-13
- Last updated
- 2017-03-21
- Results first posted
- 2017-03-21
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cardiac Ejection Fraction as Measured by Echocardiogram | 12 month visit | Mean cardiac ejection fraction as measured by echocardiogram at 12 month study visit. Cardiac ejection fractions were measured using the biplane Simpson's rule using images obtained from the apical 4 chamber views of the heart. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Cardiac Ejection Fraction as Measured by Echocardiogram | 12 month visit | All patients that received a 12 month echocardiogram evaluation | percentage of blood leaving the heart | MEAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Cardiac Ejection Fraction as Measured by Echocardiogram | Lisinopril | 54.6 | Standard Deviation 5.19 | percentage of blood leaving the heart | |
| Cardiac Ejection Fraction as Measured by Echocardiogram | Losartan | 55.2 | Standard Deviation 7.19 | percentage of blood leaving the heart |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Lisinopril | 12 | |
| Overall Study | STARTED | Losartan | 11 | |
| Overall Study | COMPLETED | Lisinopril | 12 | |
| Overall Study | COMPLETED | Losartan | 10 | |
| Overall Study | NOT COMPLETED | Lisinopril | 0 | |
| Overall Study | NOT COMPLETED | Losartan | 1 |
Source ClinicalTrials.gov
Adverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Allergic reaction to medication | Skin and subcutaneous tissue disorders | Lisinopril | 0 | 12 | 0 |
| other | Allergic reaction to medication | Skin and subcutaneous tissue disorders | Losartan | 1 | 10 | 1 |
| other | Cardiomyopathy | Cardiac disorders | Lisinopril | 0 | 12 | 0 |
| other | Cardiomyopathy | Cardiac disorders | Losartan | 1 | 10 | 1 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Lisinopril | ||
| Total, all-cause mortality | Losartan | ||
| Total, other adverse events | Lisinopril | 0 | 12 |
| Total, other adverse events | Losartan | 2 | 10 |
| Total, serious adverse events | Lisinopril | 0 | 12 |
| Total, serious adverse events | Losartan | 0 | 10 |
Source ClinicalTrials.gov
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Lisinopril vs Losartan: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01982695
GET https://conductscience.org/api/trials/v1/NCT01982695/registered